Sarah Woodside, Daniel Nguyen, Jessica Smith, Austin Udy, Teresa Whetstone, Joe Zhang
{"title":"Incidental Renal Cell Carcinoma in an Active-Duty Fighter Pilot.","authors":"Sarah Woodside, Daniel Nguyen, Jessica Smith, Austin Udy, Teresa Whetstone, Joe Zhang","doi":"10.3357/AMHP.6311.2026","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Renal cell carcinoma (RCC) is a relatively uncommon medical illness among the civilian population and less common within the U.S. Air Force pilot population. While the classic presentation of RCC is macroscopic hematuria, flank pain, and palpable flank mass, these are rarely seen. RCC is often clinically silent and it is not uncommon for RCC to be incidentally discovered in an already highly metastasized state.</p><p><strong>Case report: </strong>A 44-yr-old male fifth-generation fighter pilot presented with acute chronic lower back pain who was evaluated with routine x-rays, which led to the incidental discovery of RCC. The patient underwent left nephrectomy for a potential cure. He was initially diagnosed with Stage II RCC but was later found to have metastatic disease to the lungs. The patient subsequently underwent immunotherapy and was able to finish his military career in a nonflying status prior to his death approximately 7 yr after his initial diagnosis.</p><p><strong>Discussion: </strong>Our patient was treated with the classic surgical approach, but at the time of surgery, the tumor had already spread to the vasculature and metastasized. The late-stage RCC at diagnosis necessitated a nonflying status for the remainder of his military career. Training costs of a fifth-generation fighter pilot as of 2018 reached upwards of $10.9 million. The pilot described had significant military training and flying experience, which likely incurred an estimated $30 million in loss. This case highlights the need for close monitoring and proactive screening of this special patient population. Woodside S, Nguyen D, Smith J, Udy A, Whetsone T, Zhang J. Incidental renal cell carcinoma in an active-duty fighter pilot. Aerosp Med Hum Perform. 2026; 97(7):539-542.</p>","PeriodicalId":7463,"journal":{"name":"Aerospace medicine and human performance","volume":"97 7","pages":"539-542"},"PeriodicalIF":0.8000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aerospace medicine and human performance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3357/AMHP.6311.2026","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOPHYSICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Renal cell carcinoma (RCC) is a relatively uncommon medical illness among the civilian population and less common within the U.S. Air Force pilot population. While the classic presentation of RCC is macroscopic hematuria, flank pain, and palpable flank mass, these are rarely seen. RCC is often clinically silent and it is not uncommon for RCC to be incidentally discovered in an already highly metastasized state.
Case report: A 44-yr-old male fifth-generation fighter pilot presented with acute chronic lower back pain who was evaluated with routine x-rays, which led to the incidental discovery of RCC. The patient underwent left nephrectomy for a potential cure. He was initially diagnosed with Stage II RCC but was later found to have metastatic disease to the lungs. The patient subsequently underwent immunotherapy and was able to finish his military career in a nonflying status prior to his death approximately 7 yr after his initial diagnosis.
Discussion: Our patient was treated with the classic surgical approach, but at the time of surgery, the tumor had already spread to the vasculature and metastasized. The late-stage RCC at diagnosis necessitated a nonflying status for the remainder of his military career. Training costs of a fifth-generation fighter pilot as of 2018 reached upwards of $10.9 million. The pilot described had significant military training and flying experience, which likely incurred an estimated $30 million in loss. This case highlights the need for close monitoring and proactive screening of this special patient population. Woodside S, Nguyen D, Smith J, Udy A, Whetsone T, Zhang J. Incidental renal cell carcinoma in an active-duty fighter pilot. Aerosp Med Hum Perform. 2026; 97(7):539-542.
期刊介绍:
The peer-reviewed monthly journal, Aerospace Medicine and Human Performance (AMHP), formerly Aviation, Space, and Environmental Medicine, provides contact with physicians, life scientists, bioengineers, and medical specialists working in both basic medical research and in its clinical applications. It is the most used and cited journal in its field. It is distributed to more than 80 nations.